{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T05:28:05Z","timestamp":1789450085475,"version":"build-2803163510"},"reference-count":32,"publisher":"American Society for Microbiology","issue":"5","license":[{"start":{"date-parts":[[2008,5,1]],"date-time":"2008-05-01T00:00:00Z","timestamp":1209600000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Clin Vaccine Immunol"],"published-print":{"date-parts":[[2008,5]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n          <jats:p>\n            The role of opsonophagocytosis (OP) in protection against meningococcal disease is controversial because patients with deficiencies in terminal complement proteins whose sera support OP but not bactericidal activity (BA) are at greatly increased risk of disease. We assayed complement-mediated BA and OP bactericidal activity in sera from 32 adults immunized with an outer membrane vesicle vaccine given alone or combined with an investigational recombinant protein, genome-derived neisserial antigen (GNA2132). The sera were heat inactivated to remove internal complement activity, and BA was measured with exogenous nonimmune human serum as a complement source. OP was measured with human polymorphonuclear cells (PMNs) and C6-depleted complement, which without PMNs did not support BA. Before immunization, 9 to 19% of sera from subjects in both vaccine groups combined had BA titers of \u22651:4, which increased to 41 to 72% after immunization (\n            <jats:italic>P<\/jats:italic>\n            &lt; 0.01 against each of three test strains). The percentages of sera with OP titers of \u22651:5 were 3 to 16%, which increased to 55 to 72% (\n            <jats:italic>P<\/jats:italic>\n            &lt; 0.001 for each strain). Most postimmunization BA-positive sera were OP positive, but 10 to 37% of BA-negative sera also were OP positive. Comparing the two vaccine groups, there were no significant differences in the percentages of sera with BA or OP activity except for a higher percentage of OP against one strain in postimmunization sera from subjects in the combination vaccine group (\n            <jats:italic>P<\/jats:italic>\n            \u2264 0.02). The data support independent roles for serum BA and OP bactericidal activity in protection against group B disease.\n          <\/jats:p>","DOI":"10.1128\/cvi.00036-08","type":"journal-article","created":{"date-parts":[[2008,3,20]],"date-time":"2008-03-20T00:55:09Z","timestamp":1205974509000},"page":"799-804","update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":46,"title":["Vaccine-Induced Opsonophagocytic Immunity to\n            <i>Neisseria meningitidis<\/i>\n            Group B"],"prefix":"10.1128","volume":"15","author":[{"given":"J. S.","family":"Plested","sequence":"first","affiliation":[{"name":"Center for Immunobiology and Vaccine Development, Children's Hospital Oakland Research Institute, Oakland, California 94609"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D. M.","family":"Granoff","sequence":"additional","affiliation":[{"name":"Center for Immunobiology and Vaccine Development, Children's Hospital Oakland Research Institute, Oakland, California 94609"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1093\/infdis\/168.1.227","volume":"168","year":"1993","unstructured":"Andreoni, J., H. Kayhty, and P. Densen. 1993. Vaccination and the role of capsular polysaccharide antibody in prevention of recurrent meningococcal disease in late complement component-deficient individuals. J. Infect. Dis.168:227-231.","journal-title":"J. Infect. Dis."},{"key":"e_1_3_2_3_2","first-page":"780","volume":"10","year":"2003","unstructured":"Andrews, N., R. Borrow, and E. Miller. 2003. Validation of serological correlate of protection for meningococcal C conjugate vaccine by using efficacy estimates from postlicensure surveillance in England. Clin. Diagn. Lab. Immunol.10:780-786.","journal-title":"Clin. Diagn. Lab. Immunol."},{"key":"e_1_3_2_4_2","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1586\/14760584.3.1.77","volume":"3","year":"2004","unstructured":"Balmer, P., and R. Borrow. 2004. Serologic correlates of protection for evaluating the response to meningococcal vaccines. Expert Rev. Vaccines3:77-87.","journal-title":"Expert Rev. Vaccines"},{"key":"e_1_3_2_5_2","doi-asserted-by":"crossref","first-page":"2222","DOI":"10.1016\/j.vaccine.2005.01.051","volume":"23","year":"2005","unstructured":"Borrow, R., P. Balmer, and E. Miller. 2005. Meningococcal surrogates of protection-serum bactericidal antibody activity. Vaccine23:2222-2227.","journal-title":"Vaccine"},{"key":"e_1_3_2_6_2","doi-asserted-by":"crossref","first-page":"5093","DOI":"10.1016\/j.vaccine.2006.03.091","volume":"24","year":"2006","unstructured":"Borrow, R., G. M. Carlone, N. Rosenstein, M. Blake, I. Feavers, D. Martin, W. Zollinger, J. Robbins, I. Aaberge, D. M. Granoff, E. Miller, B. Plikaytis, L. van Alphen, J. Poolman, R. Rappuoli, L. Danzig, J. Hackell, B. Danve, M. Caulfield, S. Lambert, and D. Stephens. 2006. Neisseria meningitidis group B correlates of protection and assay standardization. International meeting report, Emory University, Atlanta, Georgia, United States, 16-17 March 2005. Vaccine24:5093-5107.","journal-title":"Vaccine"},{"key":"e_1_3_2_7_2","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1182\/blood.V92.5.1526","volume":"92","year":"1998","unstructured":"Carlsson, L. E., S. Santoso, G. Baurichter, H. Kroll, S. Papenberg, P. Eichler, N. A. Westerdaal, V. Kiefel, J. G. van de Winkel, and A. Greinacher. 1998. Heparin-induced thrombocytopenia: new insights into the impact of the Fc\u03b3RIIa-R-H131 polymorphism. Blood92:1526-1531.","journal-title":"Blood"},{"key":"e_1_3_2_8_2","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1017\/S0950268805004954","volume":"134","year":"2006","unstructured":"Dyet, K. H., and D. R. Martin. 2006. Clonal analysis of the serogroup B meningococci causing New Zealand's epidemic. Epidemiol. Infect.134:377-383.","journal-title":"Epidemiol. Infect."},{"key":"e_1_3_2_9_2","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1007\/BF02918259","volume":"12","year":"1993","unstructured":"Figueroa, J., J. Andreoni, and P. Densen. 1993. Complement deficiency states and meningococcal disease. Immunol. Res.12:295-311.","journal-title":"Immunol. Res."},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.4.3.359"},{"key":"e_1_3_2_11_2","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1046\/j.1365-2249.1998.00738.x","volume":"114","year":"1998","unstructured":"Fijen, C. A., E. J. Kuijper, M. Drogari-Apiranthitou, Y. Van Leeuwen, M. R. Daha, and J. Dankert. 1998. Protection against meningococcal serogroup ACYW disease in complement-deficient individuals vaccinated with the tetravalent meningococcal capsular polysaccharide vaccine. Clin. Exp. Immunol.114:362-369.","journal-title":"Clin. Exp. Immunol."},{"key":"e_1_3_2_12_2","first-page":"585","year":"1989","unstructured":"Fijen, C. A., E. J. Kuijper, A. J. Hannema, A. G. Sjoholm, and J. P. van Putten. 1989. Complement deficiencies in patients over ten years old with meningococcal disease due to uncommon serogroups. Lancetii:585-588.","journal-title":"Lancet"},{"key":"e_1_3_2_13_2","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1093\/clinids\/18.5.780","volume":"18","year":"1994","unstructured":"Fijen, C. A., E. J. Kuijper, H. G. Tjia, M. R. Daha, and J. Dankert. 1994. Complement deficiency predisposes for meningitis due to nongroupable meningococci and Neisseria-related bacteria. Clin. Infect. Dis.18:780-784.","journal-title":"Clin. Infect. Dis."},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1128\/IAI.00466-06"},{"key":"e_1_3_2_15_2","doi-asserted-by":"crossref","first-page":"2377","DOI":"10.1016\/S0264-410X(99)00036-5","volume":"17","year":"1999","unstructured":"Fischer, M., G. M. Carlone, J. Holst, D. Williams, D. S. Stephens, and B. A. Perkins. 1999. Neisseria meningitidis serogroup B outer membrane vesicle vaccine in adults with occupational risk for meningococcal disease. Vaccine17:2377-2383.","journal-title":"Vaccine"},{"key":"e_1_3_2_16_2","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1093\/clinids\/7.4.504","volume":"7","year":"1985","unstructured":"Frasch, C. E., W. D. Zollinger, and J. T. Poolman. 1985. Serotype antigens of Neisseria meningitidis and a proposed scheme for designation of serotypes. Rev. Infect. Dis.7:504-510.","journal-title":"Rev. Infect. Dis."},{"key":"e_1_3_2_17_2","first-page":"67","volume":"14","year":"1991","unstructured":"Fredriksen, J. H., E. Rosenqvist, E. Wedege, K. Bryn, G. Bjune, L. O. Froholm, A. K. Lindbak, B. Mogster, E. Namork, U. Rye, et al. 1991. Production, characterization and control of MenB-vaccine \u201cFolkehelsa\u201d: an outer membrane vesicle vaccine against group B meningococcal disease. NIPH Ann.14:67-79.","journal-title":"NIPH Ann."},{"key":"e_1_3_2_18_2","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1084\/jem.129.6.1307","volume":"129","year":"1969","unstructured":"Goldschneider, I., E. C. Gotschlich, and M. S. Artenstein. 1969. Human immunity to the meningococcus. I. The role of humoral antibodies. J. Exp. Med.129:1307-1326.","journal-title":"J. Exp. Med."},{"key":"e_1_3_2_19_2","first-page":"399","year":"2008","unstructured":"Granoff, D. M., L. Harrison, and R. Borrow. 2008. Meningoccal vaccines, p. 399-434. In S. A. Plotkin, P. Offit, and W. A. Orenstein (ed.), Vaccines, 5th ed. Saunders Elsevier, Philadelphia, PA.","journal-title":"Vaccines"},{"key":"e_1_3_2_20_2","unstructured":"Complement: a practical approach 1977"},{"key":"e_1_3_2_21_2","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1086\/514232","volume":"177","year":"1998","unstructured":"Perkins, B. A., K. Jonsdottir, H. Briem, E. Griffiths, B. D. Plikaytis, E. A. Hoiby, E. Rosenqvist, J. Holst, H. Nokleby, F. Sotolongo, G. Sierra, H. C. Campa, G. M. Carlone, D. Williams, J. Dykes, D. Kapczynski, E. Tikhomirov, J. D. Wenger, and C. V. Broome. 1998. Immunogenicity of two efficacious outer membrane protein-based serogroup B meningococcal vaccines among young adults in Iceland. J. Infect. Dis.177:683-691.","journal-title":"J. Infect. Dis."},{"key":"e_1_3_2_22_2","doi-asserted-by":"crossref","first-page":"1816","DOI":"10.1126\/science.287.5459.1816","volume":"287","year":"2000","unstructured":"Pizza, M., V. Scarlato, V. Masignani, M. M. Giuliani, B. Arico, M. Comanducci, G. T. Jennings, L. Baldi, E. Bartolini, B. Capecchi, C. L. Galeotti, E. Luzzi, R. Manetti, E. Marchetti, M. Mora, S. Nuti, G. Ratti, L. Santini, S. Savino, M. Scarselli, E. Storni, P. Zuo, M. Broeker, E. Hundt, B. Knapp, E. Blair, T. Mason, H. Tettelin, D. W. Hood, A. C. Jeffries, N. J. Saunders, D. M. Granoff, J. C. Venter, E. R. Moxon, G. Grandi, and R. Rappuoli. 2000. Identification of vaccine candidates against serogroup B meningococcus by whole-genome sequencing. Science287:1816-1820.","journal-title":"Science"},{"key":"e_1_3_2_23_2","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1097\/00005792-199311000-00002","volume":"72","year":"1993","unstructured":"Platonov, A. E., V. B. Beloborodov, and I. V. Vershinina. 1993. Meningococcal disease in patients with late complement component deficiency: studies in the U.S.S.R. Medicine (Baltimore)72:374-392.","journal-title":"Medicine (Baltimore)"},{"key":"e_1_3_2_24_2","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1159\/000070219","volume":"130","year":"2003","unstructured":"Platonov, A. E., I. V. Vershinina, H. Kayhty, C. A. Fijen, R. Wurzner, and E. J. Kuijper. 2003. Antibody-dependent killing of meningococci by human neutrophils in serum of late complement component-deficient patients. Int. Arch. Allergy Immunol.130:314-321.","journal-title":"Int. Arch. Allergy Immunol."},{"key":"e_1_3_2_25_2","doi-asserted-by":"crossref","first-page":"4437","DOI":"10.1016\/S0264-410X(03)00440-7","volume":"21","year":"2003","unstructured":"Platonov, A. E., I. V. Vershinina, E. J. Kuijper, R. Borrow, and H. Kayhty. 2003. Long term effects of vaccination of patients deficient in a late complement component with a tetravalent meningococcal polysaccharide vaccine. Vaccine21:4437-4447.","journal-title":"Vaccine"},{"key":"e_1_3_2_26_2","doi-asserted-by":"publisher","DOI":"10.1128\/iai.63.12.4642-4652.1995"},{"key":"e_1_3_2_27_2","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1093\/infdis\/155.6.1266","volume":"155","year":"1987","unstructured":"Ross, S. C., P. J. Rosenthal, H. M. Berberich, and P. Densen. 1987. Killing of Neisseria meningitidis by human neutrophils: implications for normal and complement-deficient individuals. J. Infect. Dis.155:1266-1275.","journal-title":"J. Infect. Dis."},{"key":"e_1_3_2_28_2","doi-asserted-by":"crossref","first-page":"674","DOI":"10.3201\/eid1004.030247","volume":"10","year":"2004","unstructured":"Russell, J. E., K. A. Jolley, I. M. Feavers, M. C. Maiden, and J. Suker. 2004. PorA variable regions of Neisseria meningitidis. Emerg. Infect. Dis.10:674-678.","journal-title":"Emerg. Infect. Dis."},{"key":"e_1_3_2_29_2","first-page":"1520","volume":"281","year":"1999","unstructured":"Tappero, J. W., R. Lagos, A. M. Ballesteros, B. Plikaytis, D. Williams, J. Dykes, L. L. Gheesling, G. M. Carlone, E. A. Hoiby, J. Holst, H. Nokleby, E. Rosenqvist, G. Sierra, C. Campa, F. Sotolongo, J. Vega, J. Garcia, P. Herrera, J. T. Poolman, and B. A. Perkins. 1999. Immunogenicity of 2 serogroup B outer-membrane protein meningococcal vaccines: a randomized controlled trial in Chile. JAMA281:1520-1527.","journal-title":"JAMA"},{"key":"e_1_3_2_30_2","doi-asserted-by":"publisher","DOI":"10.1128\/CVI.00102-07"},{"key":"e_1_3_2_31_2","doi-asserted-by":"publisher","DOI":"10.1128\/CVI.00341-07"},{"key":"e_1_3_2_32_2","doi-asserted-by":"crossref","first-page":"1730","DOI":"10.1086\/379375","volume":"188","year":"2003","unstructured":"Welsch, J. A., G. R. Moe, R. Rossi, J. Adu-Bobie, R. Rappuoli, and D. M. Granoff. 2003. Antibody to genome-derived neisserial antigen 2132, a Neisseria meningitidis candidate vaccine, confers protection against bacteremia in the absence of complement-mediated bactericidal activity. J. Infect. Dis.188:1730-1740.","journal-title":"J. Infect. Dis."},{"key":"e_1_3_2_33_2","first-page":"430","volume":"83","year":"1991","unstructured":"Wurzner, R., A. Orren, P. Potter, B. P. Morgan, D. Ponard, P. Spath, M. Brai, M. Schulze, L. Happe, and O. Gotze. 1991. Functionally active complement proteins C6 and C7 detected in C6- and C7-deficient individuals. Clin. Exp. Immunol.83:430-437.","journal-title":"Clin. Exp. Immunol."}],"container-title":["Clinical and Vaccine Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/CVI.00036-08","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/CVI.00036-08","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,29]],"date-time":"2021-07-29T20:40:31Z","timestamp":1627591231000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/CVI.00036-08"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,5]]},"references-count":32,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2008,5]]}},"alternative-id":["10.1128\/CVI.00036-08"],"URL":"https:\/\/doi.org\/10.1128\/cvi.00036-08","relation":{},"ISSN":["1556-6811","1556-679X"],"issn-type":[{"value":"1556-6811","type":"print"},{"value":"1556-679X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,5]]},"assertion":[{"value":"2008-01-29","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2008-03-12","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-12-18","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}